Sign in to view content

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)

Dante Joseph Pieramici, MD

Video
Published 2020

Related

Future DME Therapeutics
Updates from the Field
2017
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more